Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons
Author:
Affiliation:
1. National Advisory Unit on Rehabilitation in Rheumatology
2. Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Funder
Biogen
Publisher
Oxford University Press (OUP)
Subject
Pharmacology (medical),Rheumatology
Link
http://academic.oup.com/rheumatology/article-pdf/56/suppl_4/iv49/24245814/kex276.pdf
Reference111 articles.
1. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update;Smolen;Ann Rheum Dis,2014
2. Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis;Singh;Cochrane Database Syst Rev,2016
3. Inequities in access to biologic and synthetic DMARDs across 46 European countries;Putrik;Ann Rheum Dis,2014
4. Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country’s wealth?;Putrik;Ann Rheum Dis,2014
5. Pharmacoeconomics of cancer therapies: considerations with the introduction of biosimilars;Henry;Semin Oncol,2014
Cited by 38 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Improving patient access to biosimilar tumor necrosis factor inhibitors in immune-mediated inflammatory disease: lessons learned from Norway;Expert Opinion on Biological Therapy;2023-11
2. Biosimilars in the treatment of rheumatoid arthritis: a pharmacokinetic overview;Expert Opinion on Drug Metabolism & Toxicology;2023-10-25
3. Real-world evidence of the use of the infliximab biosimilar SB2: data from the PERFUSE study;Rheumatology Advances in Practice;2023-01-01
4. Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry;RMD Open;2022-11
5. The Knowledge, Opinions, Attitudes of Physicians About Biosimilar Drugs: A University Hospital Data;Journal of Basic and Clinical Health Sciences;2022-04-21
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3